About me
Tolga Tanguler joined Alnylam in January 2021 as Executive Vice President and Chief Commercial Officer with more than 20 years of experience in the global biopharmaceutical industry. At Alnylam, Tolga plays a pivotal role in scaling the company on a global stage, having expanded its commercial presence to more than 60 markets and tripled the number of patients served and product sales within three years.
Tolga has led commercialization efforts across a broad range of therapeutic areas, from early development to product launch and growth management. His leadership portfolio includes well-known medicines such as Viagra, Eliquis, and Ultomiris. Prior to Alnylam, he served as Head of U.S. at Alexion, where he led its transformational growth through first-in-class neurology product launches. Tolga spent most of his formative years at Pfizer, where he notably established and led the North America rare disease unit as its president, spearheading the company’s gene therapy innovation efforts.
Tolga holds a Bachelor of Science in Finance and Economics from Istanbul University and an MBA in Marketing and Supply Chain Management from Michigan State University. He also completed postgraduate studies in Marketing at the University of California, Santa Barbara. Tolga is a member of the Board of Directors of Lexeo Therapeutics, a clinical stage genetic medicine company.
